Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02681055 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
A Phase 2 study, sponsored by MediciNova.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02681055 is a Phase 2 study that has completed, run by MediciNova. The registered enrollment target is 19 participants.
The verdict
NCT02681055, a Phase 2 study, has completed, sponsored by MediciNova.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in non-alcoholic steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) subjects with hypertriglyceridemia.
Interventions
- DRUG MN-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02681055
The ClinicalTrials.gov registry entry for NCT02681055 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediciNova, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MN-001 is the first listed.
NCT02681055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02681055 about?
NCT02681055 is a clinical study titled "Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects". This is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in non-alcoholic steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) subjects with hypertriglyceridemia.
What is the current status of trial NCT02681055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-03. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT02681055?
The interventions under investigation include: MN-001 (DRUG).
Who is sponsoring clinical trial NCT02681055?
This trial is sponsored by MediciNova, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.